TeamShould you stack tirzepatide and retatrutide?

The useful first comparison is compound versus compound. Tirzepatide is a dual GIP and GLP-1 receptor agonist, while retatrutide adds glucagon receptor activity to GIP and GLP-1 activity. Both have produced substantial weight-loss results in controlled monotherapy trials. In SURMOUNT-1, tirzepatide reached 22.5% mean weight loss at 72 weeks in the 15 mg group under the efficacy estimand. In TRIUMPH-1, retatrutide reached 28.3% at 80 weeks in the 12 mg group. Those numbers come from different studies, populations, durations, and estimands, so they are useful benchmarks but not a head-to-head result. There is currently no controlled evidence showing that combining tirzepatide and retatrutide improves outcomes over using either one alone. Because their receptor activity overlaps, a multi-compound result also cannot tell you which product delivered the benefit or caused an unwanted effect. For buyers comparing the two research lanes, use a five-part checklist: 1. Compare the evidence and receptor profile separately. 2. Calculate effective price per mg using the after-code product price plus shipping, divided by the total labeled mg. 3. Match the vial lot or batch to the current COA. 4. Require identity and purity results plus a separate quantitative net-content result, since 99% purity does not prove the vial contains the labeled amount. 5. Check sterility and endotoxin documentation where applicable before letting a low price win. PeptidePub has a side-by-side evidence comparison at https://www.peptidepub.com/compare/retatrutide-vs-tirzepatide. Current buyer comparisons are at https://www.peptidepub.com/prices/retatrutide and https://www.peptidepub.com/prices/tirzepatide, with vendor testing details at https://www.peptidepub.com/vendors.